Oxaliplatine Hikma

Oxaliplatin, the active ingredient in Oxaliplatine Hikma, is a platinum compound presented as an intravenous solution for intravenous use. It treats colorectal cancer and is employed as adjuvant therapy for stage III colon cancer in adult patients.

GNH USA supplies Oxaliplatine Hikma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide, with the product sourced from EU‑regulated manufacturers and meeting global quality standards. The company provides regulatory documentation and logistics support to ensure safe delivery to qualified healthcare institutions.

Oxaliplatin is used in oncology protocols that target colorectal malignancies and related disease stages. - Colorectal cancer: administered in combination regimens to inhibit tumor growth and improve response rates. - Stage III colon cancer (adjuvant): given after surgical resection to reduce the risk of disease recurrence. - Metastatic colorectal cancer: used as part of systemic therapy to control disease spread and prolong survival.

Oxaliplatin may cause a range of adverse reactions, from mild to severe, that require monitoring during therapy.

Common Side Effects: - Nausea and vomiting: transient gastrointestinal upset. - Peripheral neuropathy: tingling or numbness, often dose‑related. - Fatigue: generalized tiredness affecting daily activities. - Neutropenia: reduced white blood cell count increasing infection risk. - Anemia: lowered red blood cell levels causing weakness. - Thrombocytopenia: decreased platelets leading to easy bruising.

Serious or Rare Side Effects: - Severe allergic reactions: anaphylaxis or hypersensitivity requiring immediate care. - Pulmonary toxicity: interstitial lung disease or acute respiratory distress. - Severe neutropenia with fever: potential sepsis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Cardiac arrhythmias: irregular heart rhythms. - Tumor lysis syndrome: rapid tumor cell breakdown causing metabolic disturbances.

Prior to initiating Oxaliplatin therapy, clinicians should assess patient-specific risk factors and monitor relevant parameters. - Renal function: evaluate creatinine clearance and adjust dosing if impaired. - Pre‑existing neuropathy: avoid or use with caution in patients with baseline nerve damage. - Hematologic status: perform baseline CBC and monitor for cytopenias. - Electrolyte balance: correct hypomagnesemia and other electrolyte abnormalities. - Hypersensitivity: discontinue if severe allergic reaction occurs. - Store at ambient temperature: keep in original container, protect from moisture and light.

Oxaliplatin can interact with other agents that affect renal function, hematopoiesis, or immune response.

Major Interactions (Avoid): - Concurrent platinum agents: additive toxicity and overlapping side‑effects. - Live vaccines: increased risk of infection due to immunosuppression. - High‑dose radiation therapy: potentiates tissue damage.

Moderate Interactions (Monitor Closely): - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may worsen renal impairment. - Loop diuretics: can exacerbate electrolyte disturbances and nephrotoxicity. - Anticoagulants/antiplatelet agents: heightened bleeding risk with thrombocytopenia. - Other myelosuppressive chemotherapy: cumulative bone‑marrow suppression. - Magnesium supplements: may reduce neurotoxicity but require monitoring.